Skip to main content
PegBio Co., Ltd. logo

PegBio Co., Ltd. — Investor Relations & Filings

Ticker · 2565 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 2,123 across all filing types
Latest filing 2026-05-06 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2565

About PegBio Co., Ltd.

http://www.pegbio.com

PegBio Co., Ltd. is a biotechnology company specializing in the in-house discovery and development of innovative therapies for chronic diseases, primarily focusing on the endocrine and metabolic fields. The company leverages its proprietary HECTORTM technology system to design and screen novel molecular entities, including peptide, protein, and small-molecule drugs, targeting unmet clinical needs. PegBio's robust pipeline addresses major chronic conditions such as Type 2 Diabetes (T2DM), obesity, and metabolic dysfunction-associated steatohepatitis (MASH). Key pipeline assets include long-acting GLP-1 receptor agonists, such as Vepinatide, developed for T2DM treatment and weight management. The company emphasizes creating complementary, multi-benefit product pipelines characterized by new targets, new sites, and new mechanisms of action.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings
2026-05-06 English
2025 Annual Report
Regulatory Filings
2026-04-28 English
INSIDE INFORMATION ISSUANCE OF FILING NOTICE BY THE CSRC FOR THE H SHARE FULL CIRCULATION APPLICATION BY THE COMPANY
Share Issue/Capital Change Classification · 1% confidence The document is an exchange announcement made under the Listing Rules and Inside Information Provisions regarding the CSRC’s filing notice for the company’s H Share full circulation application. It is not a financial report, earnings release, or management discussion, but rather a regulatory update on the conversion of unlisted shares to H shares and the intended listing of those shares. This constitutes a change in the company’s capital structure. Accordingly, it falls under “Share Issue/Capital Change (SHA).”
2026-04-09 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026
Regulatory Filings Classification · 1% confidence The document is the HKEX Form FF301 “Monthly Return for Equity Issuer and Hong Kong Depositary Receipts” under Chapter 19B of the Listing Rules. It provides routine share capital and public float confirmations for the month ended 31 March 2026. It is a compliance filing submitted to the exchange, not an earnings release, management discussion, or capital-raising announcement. It does not announce the publication of another report but is itself a regulatory submission. It therefore falls under the fallback category “Regulatory Filings (RNS).”
2026-04-08 English
VOLUNTARY ANNOUNCEMENT Research Abstract Related to CR059 Accepted by the 2026 Scientific Sessions of the American Diabetes Association and Selected as a Late Breaking Abstract
Regulatory Filings Classification · 1% confidence The document is a voluntary corporate announcement about acceptance of a research abstract by an academic conference, not an earnings release, regulatory report, financial statement or meeting materials. It does not fit specialized categories such as M&A, AGM information, dividend notice, etc. It is a general company update filed on the stock exchange under Listing Rules, making it a general regulatory announcement (fallback).
2026-04-02 English
CHANGE OF JOINT COMPANY SECRETARY, AUTHORISED REPRESENTATIVE AND PROCESS AGENT AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES
Board/Management Information Classification · 1% confidence The document is an official announcement regarding changes in key corporate officers (joint company secretary, authorised representative, process agent) and a waiver application under the Listing Rules. It does not present financial results, ask for votes, or release an annual/interim report. This falls squarely under Board/Management Information, reporting senior management changes.
2026-04-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.